Procter & Gamble (NYSE:PG) is buying its way into wellness. On August 4, L Catterton announced it had signed a definitive agreement to sell Thorne, a science-backed health and wellness brand, to Procter & Gamble for $3.8 billion in cash. The deal lands a day after an August 3 analysis flagged a fiscal 2027 earnings guide that came in below expectations, weighed down by roughly $1 billion in new cost headwinds. Investors now have two stories to weigh at once: fresh expansion and a tougher near-term cost picture.
Bull Case: A Bigger Foothold In Trusted Wellness
The Thorne acquisition gives Procter & Gamble entry into a category built on clinical credibility rather than shelf space. Thorne has spent 40 years building relationships with healthcare practitioners, and L Catterton’s announcement noted the company developed a proprietary AI wellness advisor to help consumers navigate its supplement lineup, a tool practitioners can point their patients to directly.
The transaction is expected to close in the fourth quarter of 2026, an all-cash deal with no debt or equity swapped into the mix. Procter & Gamble isn’t skimping on shareholders while it shops, either. The company returned $10.2 billion in dividends and $5.0 billion in share repurchases during fiscal 2026, and it plans roughly the same combination, about $10 billion in dividends and $5 billion in buybacks, for fiscal 2027. There’s a case buried inside the company’s own guidance, too. Strip out the roughly $1 billion in commodity, energy, and transportation costs management expects to absorb next year, and core EPS would be growing at about 10% instead of the 0% to 3% baked into the outlook.
Bear Case: Guidance That Undercuts The Story
The numbers behind the fiscal 2027 outlook explain the caution. Management guided core EPS to $6.89 to $7.11, implying growth of just 0% to 3%, and pointed to roughly $1 billion in after-tax commodity, energy, and transportation costs as the main culprit. Add higher net interest expense, lower non-operating income, and unfavorable currency, and the total drag reaches $0.56 per share, wiping out about 8 percentage points of core earnings growth before the year even starts.
The trend already shows up in recent results. In the fiscal fourth quarter, net sales rose 2% year-over-year to $21.2 billion while organic sales were flat, and core EPS fell 3% to $1.43. For the full fiscal year, net sales grew 3% to $87.0 billion, but organic sales rose only 1%, and every bit of that growth came from higher prices rather than more units sold. Volume and mix didn’t move. Shares trade near $144, about 5% above their 52-week low of $137.62, or roughly 21 times fiscal 2026 core earnings of $6.89. That’s not an expensive multiple, but it isn’t cheap for a business guiding to low-single-digit growth.
What The Market Is Signaling
Hedge fund ownership of Procter & Gamble fell from 90 funds to 78 in the most recent quarter, pointing to some institutional trimming. Short interest sits at just 0.99% of float, a level that shows almost no organized bet against the stock. The forward price-to-earnings ratio of 20.83, as of August 7, is a moderate multiple for a company guiding to 0% to 3% core earnings growth. Falling fund ownership alongside such thin short interest is an unusual pairing, since the skepticism here isn’t showing up as a short bet.
Two Timelines, One Stock
Procter & Gamble is making a long-term bet on wellness while absorbing a near-term cost squeeze, and both are true at once. For the bull case to play out, Thorne needs to become more than a bolt-on, extending the company’s reach into a category growing faster than laundry detergent and diapers. The $3.8 billion price tag on Thorne shows Procter & Gamble is willing to spend for that future even as fiscal 2027 asks investors to be patient.
While we acknowledge the risk and potential of PG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PG and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
